Urine haptoglobin levels predict early renal functional decline in patients with type 2 diabetes

Kidney International

Volumn 83, Issue 6, 2013, Pages 1136-1143

  Bhensdadia, Nishant M ^a   Hunt, Kelly J ^a   Lopes Virella, Maria F ^a,b   Michael Tucker, J ^a   Mataria, Mohammad R ^a   Alge, Joseph L ^a   Neely, Benjamin A ^a   Janech, Michael G ^a,b   Arthur, John M ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

Biological markers; Chronic kidney disease; Diabetes; Diabetic nephropathy; Type 2 diabetes; Urine

Indexed keywords

AGRIN; ANGIOTENSINOGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HAPTOGLOBIN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 2; MANNAN BINDING LECTIN SERINE PROTEASE 2; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; SERINE PROTEINASE; TAMM HORSFALL GLYCOPROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; EARLY RENAL FUNCTIONAL DECLINE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DYSFUNCTION; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN URINE LEVEL; RISK ASSESSMENT;

EID: 84882259917     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.57     Document Type: Article

References (41)

1. Centers for Disease Control and Prevention (CDC). Incidence of end-stage renal disease attributed to diabetes among persons with diagnosed diabetes-United States and Puerto Rico, 1996-2007. MMWR Morb Mortal Wkly Rep 2010; 59: 1361-1366.
2. Cowie CC, Rust KF, Ford ES et al. Full accounting of diabetes and pre-diabetes in the US population in 1988-1994 and 2005-2006. Diabetes Care 2009; 32: 287-294.
3. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
4. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
5. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998; 352: 837-853.
6. Mogensen CE, Christensen CK. Predicting diabetic nephropathy in insulindependent patients. N Engl J Med 1984; 311: 89-93.
7. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984; 310: 356-360.
8. Tabaei BP, Al-Kassab AS, Ilag LL et al. Does microalbuminuria predict diabetic nephropathy? Diabetes Care 2001; 24: 1560-1566.
9. Yamada T, Komatsu M, Komiya I et al. Development, progression, and regression of microalbuminuria in Japanese patients with type 2 diabetes under tight glycemic and blood pressure control: the Kashiwa study. Diabetes Care 2005; 28: 2733-2738.
10. Gaede P, Tarnow L, Vedel P et al. Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria. Nephrol Dial Transplant 2004; 19: 2784-2788.
11. Araki S, Haneda M, Sugimoto T et al. Factors associated with frequent remission of microalbuminuria in patients with type 2 diabetes. Diabetes 2005; 54: 2983-2987.
12. Almdal T, Norgaard K, Feldt-Rasmussen B et al. The predictive value of microalbuminuria in IDDM. A five-year follow-up study. Diabetes Care 1994; 17: 120-125.
13. Pagtalunan ME, Miller PL, Jumping-Eagle S et al. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 1997; 99: 342-348.
14. Halimi JM. The emerging concept of chronic kidney disease without clinical proteinuria in diabetic patients. Diabetes Metab 2012; 38: 291-297.
15. Kramer HJ, Nguyen QD, Curhan G et al. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA 2003; 289: 3273-3277.
16. MacIsaac RJ, Tsalamandris C, Panagiotopoulos S et al. Nonalbuminuric renal insufficiency in type 2 diabetes. Diabetes Care 2004; 27: 195-200.
17. Retnakaran R, Cull CA, Thorne KI et al. Risk factors for renal dysfunction in type 2 diabetes: UK Prospective Diabetes Study. Diabetes 2006; 55: 1832-1839.
18. Yokoyama H, Sone H, Oishi M et al. Prevalence of albuminuria and renal insufficiency and associated clinical factors in type 2 diabetes: the Japan Diabetes Clinical Data Management study (JDDM15). Nephrol Dial Transplant 2009; 24: 1212-1219.
19. Afghahi H, Cederholm J, Eliasson B et al. Risk factors for the development of albuminuria and renal impairment in type 2 diabetes-the Swedish National Diabetes Register (NDR). Nephrol Dial Transplant 2011; 26: 1236-1243.
20. Penno G, Solini A, Bonora E et al. Clinical significance of nonalbuminuric renal impairment in type 2 diabetes. J Hypertens 2011; 29: 1802-1809.
21. Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 1985; 33: 278-285.
22. Pavkov ME, Knowler WC, Lemley KV et al. Early renal function decline in type 2 diabetes. Clin J Am Soc Nephrol 2012; 7: 78-84.
23. Perkins BA, Ficociello LH, Ostrander BE et al. Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes. J Am Soc Nephrol 2007; 18: 1353-1361.
24. Perkins BA, Ficociello LH, Roshan B et al. In patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria. Kidney Int 2010; 77: 57-64.
25. Merchant ML, Klein JB. Proteomic discovery of diabetic nephropathy biomarkers. Adv Chronic Kidney Dis 2010; 17: 480-486.
26. Bolignano D, Lacquaniti A, Coppolino G et al. Neutrophil gelatinaseassociated lipocalin as an early biomarker of nephropathy in diabetic patients. Kidney Blood Press Res 2009; 32: 91-98.
27. Fu WJ, Xiong SL, Fang YG et al. Urinary tubular biomarkers in short-term type 2 diabetes mellitus patients: a cross-sectional study. Endocrine 2012; 41: 82-88.
28. Nielsen SE, Schjoedt KJ, Astrup AS et al. Neutrophil Gelatinase- Associated Lipocalin (NGAL) and Kidney Injury Molecule 1 (KIM1) in patients with diabetic nephropathy: a cross-sectional study and the effects of lisinopril. Diabet Med 2010; 27: 1144-1150.
29. Schlatzer D, Maahs DM, Chance MR et al. Novel urinary protein biomarkers predicting the development of microalbuminuria and renal function decline in type 1 diabetes. Diabetes Care 2012; 35: 549-555.
30. Langlois MR, Delanghe JR. Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem 1996; 42: 1589-1600.
31. Lim YK, Jenner A, Ali AB et al. Haptoglobin reduces renal oxidative DNA and tissue damage during phenylhydrazine-induced hemolysis. Kidney Int 2000; 58: 1033-1044.
32. Katnik I. Studies on haptoglobin binding to concanavalin A. Biochim Biophys Acta 1984; 790: 8-14.
33. Katnik I, Guszczynski T, Dobryszycka W. Immunological comparison of glycopeptides obtained from haptoglobin types 1-1, 2-1 and 2-2. Arch Immunol Ther Exp 1984; 32: 111-120.
34. Nakhoul FM, Zoabi R, Kanter Y et al. Haptoglobin phenotype and diabetic nephropathy. Diabetologia 2001; 44: 602-604.
35. Melamed-Frank M, Lache O, Enav BI et al. Structure-function analysis of the antioxidant properties of haptoglobin. Blood 2001; 98: 3693-3698.
36. Weinberger MH, Miller JZ, Fineberg NS et al. Association of haptoglobin with sodium sensitivity and resistance of blood pressure. Hypertension 1987; 10: 443-446.
37. D'Armiento J, Dalal SS, Chada K. Tissue, temporal and inducible expression pattern of haptoglobin in mice. Gene 1997; 195: 19-27.
38. Agrawal L, Azad N, Emanuele NV et al. Observation on renal outcomes in the Veterans Affairs Diabetes Trial. Diabetes Care 2011; 34: 2090-2094.
39. Abraira C, Duckworth W, McCarren M et al. Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial. J Diabetes Complications 2003; 17: 314-322.
40. Duckworth WC, McCarren M, Abraira C. VA Diabetes Trial. Glucose control and cardiovascular complications: the VA Diabetes Trial. Diabetes Care 2001; 24: 942-945.
41. Nesvizhskii AI, Keller A, Kolker E et al. A statistical model for identifying proteins by tandem mass spectrometry. Anal Chem 2003; 75: 4646-4658.